A
Arima Genomics
Biotechnology company commercializing a new standard in DNA sequencing
About Arima Genomics
Arima Genomics is a pioneering company in the field of 3D genomics, providing advanced solutions that drive discovery and innovation in life sciences. The company serves a diverse range of clients, including translational and clinical researchers, by offering cutting-edge tools and technologies that enable a deeper understanding of gene regulation and disease mechanisms. Operating in the genomics market, Arima Genomics focuses on the development and commercialization of products like the Arima HiC Kit, which allows for reproducible 3D genome conformation analysis. The business model revolves around selling these high-quality kits and related services, generating revenue through direct sales to research institutions and pharmaceutical companies. By leveraging the power of 3D genomic information, Arima Genomics helps uncover novel biomarkers and therapeutic targets, particularly in cancer research. The company is grounded in science, driven by innovation, and focused on improving human health through its state-of-the-art genomic solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- San Diego, United States
- Employees
- 45
- Open positions
- 2
- Dealroom signal
- 68.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Arima Genomics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jun 2025 | $22M | $88M | John Stuelpnagel · Illumina Ventures · Cowin Venture · Berkeley Catalyst Fund | ↗ |
| SERIES B✓Equity / VC | Mar 2022 | $7M | $28M | Agilent · Cowin Venture · Berkeley Catalyst Fund · Hiaqua Investments | ↗ |
Growth signals
Latest recorded traffic for Arima Genomics is 5.4K monthly website visits, down 73% over the last three months. Arima Genomics's team declined 15.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Cowin Venture
Vectr Ventures
Agilent
Berkeley Catalyst Fund
Tech Coast Angels
Genetron Health- LVladder ventures
- HIHiaqua Investments
Series B and later3 investors entered at this stage
Illumina Ventures
John Stuelpnagel- MRMostafa Ronaghi
Other known investors3 additional known investors
University of California, San Diego
Small Business Innovation Research
Startup Leadership Program- SF
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Arima Genomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Arima Genomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.